Payment overview · 2025
General Payments
$603.59
13 reported records · 9 companies
Healthcare provider profile · identity verified
John D Bonema, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TROY, MI · NPI 1508833708
Verified facts
What the public records show
CMS Open Payments records show John D Bonema, MD received $603.59 in general payments during 2025 across 13 reported records.
Amgen Inc. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $145.76 | 24.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.59 | 23.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $125.26 | 20.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $106.66 | 17.7% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $18.75 | 3.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.49 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.00 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.02 | 2.5% | 1 | 2025 |
| Surgenex LLC | Unresolved — no canonical attribution shown | $14.06 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $603.59 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $143.59 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $125.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.26 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $106.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.91 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.91 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 504 | 127 |
| Alprazolam | Alprazolam | 502 | 106 |
| Omeprazole | Omeprazole | 476 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 471 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 397 | 105 |
| Simvastatin | Simvastatin | 311 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 68 |
| Prednisone | Prednisone | 237 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 54 |
| Lisinopril | Lisinopril | 183 | 46 |
| Tramadol Hcl | Tramadol Hcl | 166 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 157 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 145 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 41 |
| Metformin Hcl | Metformin Hcl | 140 | 44 |
| Eliquis | Apixaban | 137 | 32 |
| Losartan Potassium | Losartan Potassium | 127 | 38 |
| Benazepril Hcl | Benazepril Hcl | 126 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 40 |
| Furosemide | Furosemide | 113 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 110 | 29 |
| Finasteride | Finasteride | 106 | 28 |
| Carvedilol | Carvedilol | 98 | 29 |
| Ezetimibe | Ezetimibe | 96 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 21 |
| Bupropion Xl | Bupropion Hcl | 93 | 28 |
| Gabapentin | Gabapentin | 91 | 29 |
| Famotidine | Famotidine | 90 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 23 |
| Allopurinol | Allopurinol | 88 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 18 |
| Diazepam | Diazepam | 86 | 15 |
| Donepezil Hcl | Donepezil Hcl | 81 | 26 |
| Sertraline Hcl | Sertraline Hcl | 76 | 26 |
| Alendronate Sodium | Alendronate Sodium | 75 | 19 |
| Irbesartan | Irbesartan | 75 | 21 |
| Mounjaro | Tirzepatide | 74 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 73 | 34 |
| Trazodone Hcl | Trazodone Hcl | 73 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 36 |
| Glimepiride | Glimepiride | 69 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 59 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 18 |
| Midodrine Hcl | Midodrine Hcl | 57 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 55 | 46 |
| Synthroid | Levothyroxine Sodium | 55 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 17 |
| Lorazepam | Lorazepam | 54 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 17 |
| Xarelto | Rivaroxaban | 52 | 13 |
| Atenolol | Atenolol | 51 | 12 |
| Clonazepam | Clonazepam | 48 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 48 | suppressed |
| Cefdinir | Cefdinir | 45 | 29 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 45 | suppressed |
| Meloxicam | Meloxicam | 45 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 12 |
| Spironolactone | Spironolactone | 45 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 13 |
| Azithromycin | Azithromycin | 43 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 12 |
| Valacyclovir | Valacyclovir Hcl | 42 | 21 |
| Montelukast Sodium | Montelukast Sodium | 41 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 40 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 23 |
| Methocarbamol | Methocarbamol | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 11 |
| Valsartan | Valsartan | 37 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 17 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 20 |
| Indapamide | Indapamide | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 16 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 23 | 23 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 13 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 12 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Flurbiprofen | Flurbiprofen | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Norvasc | Amlodipine Besylate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $603.59 · 13 records | Amgen Inc. | AIRSUPRA, ArdeoGraft, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, NEFFY, NURTEC ODT, OTEZLA, PelloGraft, QULIPTA, REPATHA, RenoGraft, SurGraft, SurMatrix, UBRELVY, Wegovy, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error